Veronica Mollica

Sep 28, 2023 | europeanurology.com | Elisa Tassinari |Andrea Marchetti |Veronica Mollica |Francesco Massari

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Sep 18, 2023 | futuremedicine.com | Giacomo Nuvola |Veronica Mollica |Francesco Massari |Cristina Suarez |Cristina Suárez

The advent of immunotherapy has revolutionized the landscape of treatment in several cancers, with renal cell carcinoma (RCC) being one of the most responsive to this therapy [1]. This therapeutic approach is based on the complex interaction between the cancer and the immune system. It begins with cancer cells activating the innate and adaptive immune systems, resulting in tumor cell death.

Apr 19, 2023 | mdpi.com | Paola Valeria Marchese |Veronica Mollica |Francesco Massari |Valentina Tateo

1. Introduction 1.1. Brief History of a Therapeutic Paradigm Change: The Revolution in OncologyAt the dawn of oncology, between the end of 1800 and the beginning of 1900, just a few Cancer Centers existed worldwide, and treatments consisted of surgery, x-rays, and the very first chemotherapeutic agents. Then, the decades of chemotherapy boom arrived, from 1940 to 1970, with a great expansion of available chemotherapeutic agents and combination schemes.

Mar 31, 2023 | thelancet.com | Veronica Mollica |Francesco Massari

In The Lancet Oncology, Toni K Choueiri and colleaguesreport the findings from cohort 2 of a phase 2 trial of belzutifan plus cabozantinib in patients with renal cell carcinoma who had previously received an with one previous immune checkpoint inhibitor (28 [54%] of 52 patients enrolled) or immunotherapy and an anti-VEGF or anti-VEGFR tyrosine-kinase inhibitor (24 [46%]).